May 16th 2024
During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Entinostat Added to Nivolumab Plus Ipilimumab Shows Early Efficacy/Safety in Advanced BC
October 21st 2021In an interview with Targeted Oncology, Evanthia Roussos Torres, MD, PhD, discussed the phase 1 investigation of the safety and efficacy of entinostat administered in combination with nivolumab and ipilimumab for the treatment of advanced HER2-negative breast cancer.
Read More
monarchE Update Shows Sustained Benefit of Adjuvant Abemaciclib for HR+/HER2- Early Breast Cancer
October 18th 2021New findings from the phase 3 monarchE recently led to an FDA approval for abemaciclib. Joyce O’Shaughnessy, MD, presented the long-term analysis results during an ESMO Virtual Plenary.
Read More
O’Regan Highlights Advances in Management of Metastatic Breast Cancer Across Subtypes
October 13th 2021In an interview with Targeted Oncology for Metastatic Breast Cancer Awareness Day, O’Regan discussed how the metastatic breast cancer landscape has changed and suggested potential regimens that could further that change.
Read More
Phase 1 Study Explores Entinostat With Nivo/Ipi in HER2-Negative Breast Cancer
October 7th 2021Evanthia Roussos Torres, MD, PhD, discusses the study design of the phase 1 trail evaluating entinostat, nivolumab, and ipilimumab in patients with locally advanced or metastatic HER2-negative breast cancer that cannot be removed by surgery.
Watch
In ER+/HER2– Early Breast Cancer, Giredestrant Induces Greater Ki67 Suppression Vs Anastrozole
September 21st 2021In patients with estrogen receptor–positive, HER2-negative early breast cancer, giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole.
Read More
In the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, the combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone.
Read More
pCR, EFS, Improved with Neoadjuvant Carboplatin Plus Paclitaxel, Without Veliparib in TNBC
September 17th 2021Pathological complete response rates and event-free survival in patients with treatment-naïve triple-negative breast cancer were improved with The addition of carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide.
Read More
Buparlisib Treatment Begins in Combination With AN0025 and Atezolizumab for Advanced Solid Tumors
September 9th 2021The first patient with a locally advanced or metastatic solid tumor has been dosed with buparlisib in combination with A0025 with or without atezolizumab in a phase 1a clinical trial.
Read More
Atezolizumab’s Unresectable Locally Advanced or mTNBC Indication Withdrawn from US Market
August 27th 2021Atezolizumab plus nab-paclitaxel will no longer be a treatment option for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer following Roche's withdraw of the indication from the United States market.
Read More
SITC Releases Immunotherapy Clinical Practice Guideline for Breast Cancer
August 23rd 2021In the wake of immunotherapy combinations becoming available in breast cancer, including triple-negative breast cancer, the Society for Immunotherapy of Cancer has published clinical practice guidelines for physicians treating in this setting.
Read More
Somatic Gene Alterations Correlate With Resistance in Black Patients With Luminal Breast Tumors
August 17th 2021Yael Simons, MD, discusses the study of somatic driver gene alterations in a consecutive series of luminal breast tumors in Black patients, which received an American Society of Clinical Oncology Merit Award.
Watch
Eflapegrastim Still Not Approved by FDA After New Complete Response Letter
August 6th 2021The FDA has issued a complete response letter to the developer of eflapegrastim, for which a biologics license application was submitted for the treatment of chemotherapy-induced neutropenia. The FDA has cited manufacturing deficiencies and is requiring that the facilities be reinspected.
Read More
FDA Approves Pembrolizumab and Chemotherapy for High-risk Early-Stage TNBC
July 27th 2021The FDA has granted approval to pembrolizumab for the treatment of patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery.
Read More
Pembrolizumab Plus Chemotherapy Significantly Reduces the Risk of EFS Events in TNBC
July 16th 2021The combination of the ant-PD-1 inhibitor, pembrolizumab plus chemotherapy before surgery continued by pembrolizumab as a single agent led to statistically significant event-free survival result versus neoadjuvant chemotherapy alone in patients with high-risk early-stage triple-negative breast cancer.
Read More
OS Improves With Addition of Ribociclib/Endocrine Therapy in Advanced Breast Cancer
July 8th 2021Regardless of age the combination of ribociclib and endocrine therapy led to improved overall survival in pre- or postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Read More
Atezolizumab Plus Carboplatin Induces Early Efficacy Signals in Invasive Lobular Breast Cancer
July 6th 2021Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression.
Read More